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Malnutrition is a common complication in patients on dialysis
and is strongly associated with poor prognosis. Effective
therapy could substantially improve morbidity and mortality,
but neither enteral nor parenteral supplementation provide
long-term benefit because of the strong appetite suppression
seen in such patients. We performed a double-blinded
randomized crossover study of a week-long treatment with
daily subcutaneous ghrelin, a gut hormone that regulates
hunger through the hypothalamus, in a group of 12
malnourished dialysis patients. Ghrelin administration
increased ghrelin levels in circulation, modestly reduced
blood pressure for up to 2 h, and immediately and
significantly increased appetite, with an increase in energy
intake noted at the first study meal. Persistence of this effect
throughout the week was confirmed with food diaries and
final study meals. Energy expenditure, measured with free-
living pulse and motion monitors, was unchanged by ghrelin.
Our study shows that daily treatment with ghrelin achieves a
sustained positive change in energy balance in malnourished
dialysis patients. Direct manipulation of appetite with ghrelin
or its analogs represents an attractive and promising
therapeutic strategy for this difficult clinical problem.
Kidney International (2009) 76, 199–206; doi:10.1038/ki.2009.114;
published online 22 April 2009
KEYWORDS: appetite; dialysis; energy expenditure; hormones; malnutrition;
renal failure
Despite continuing progress in the management of end-stage
renal disease, mortality of patients on maintenance dialysis
remains unacceptably high. Malnutrition is a common and
early feature of chronic kidney disease,1,2 and is strongly
associated with increased mortality in dialysis patients.3–6
Although it may reflect inadequate dialysis or acute
comorbid pathology, in the majority of cases no reversible
cause can be identified. The prognostic consequence of poor
nutrition reverses the usual relationship between mortality
and body mass index or cholesterol seen in the general
population, so that the most obese dialysis patients with the
highest cholesterol have the best outlook.7,8 Many markers of
malnutrition have been linked with poor prognosis, and
some, including albumin and cholesterol, have been shown to
predict mortality far in advance,9–11 suggesting the presence
of a specific chronic pathological process.
Malnutrition is the result of a persistent deficit in energy
balance, because of a mismatch between energy intake and
energy expenditure. Resting energy expenditure in dialysis
patients does not differ from that of healthy, matched
controls,12 and poor energy intake because of reduced
appetite is believed to be the major contributor to
malnutrition,13 although dialytic glucose absorption in
peritoneal dialysis may ameliorate this to some extent.
Although the mechanism underlying this reduction in
appetite is poorly defined, recent work in animal models
suggests that abnormalities in hypothalamic appetite circuits
may be important.14
Advances in the understanding of appetite regulation may
enable direct therapeutic manipulation of food intake. In
particular, the gut hormone ghrelin has been identified as a
unique circulating hunger signal,15 acting through the
hypothalamus, and physiologically implicated in the initia-
tion of meals and quantity of energy intake.16–19 Ghrelin
administration increases short-term food intake in rodents20
and humans,21 and in rodents, repeated administration over
a number of weeks increases body weight.22,23
We have previously shown, in a group of malnourished
patients receiving maintenance peritoneal dialysis, that
spontaneous energy intake is increased after a single
subcutaneous injection of ghrelin.24 However, short-term
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increases in food intake are usually associated with
subsequent compensatory decline in appetite or increase in
energy expenditure to maintain energy homeostasis, and
such effects would limit any potential therapeutic effect of
ghrelin administration. We therefore sought to analyze the
efficacy of repeated ghrelin administration in malnourished
dialysis patients, and to extend our analysis of the
physiological effects, particularly with respect to the relative
importance of acyl and total ghrelin levels.
RESULTS
This study compared daily subcutaneous administration of
ghrelin with saline placebo in a randomized double-blinded
crossover design (Figure 1). Stable patients with evidence of
malnutrition were enrolled from the maintenance dialysis
program of a large UK renal center.
Twenty-three eligible patients were screened, after which
12 were randomized into the study: baseline characteristics
are shown in Table 1. All patients were malnourished with at
least two of six predefined markers of malnutrition (Table 1).
Mean albumin was 32.4 g/l, and mean body mass index
24.3 kg/m2. All patients were clinically well at study
enrollment and dialysis delivery was consistent with UK
Renal Association and the NKF KDOQI clinical guidelines.
Eleven patients completed the study according to the
protocol, between June 2006 and March 2007 – one patient
randomized to receive saline during the first study week
developed a venous catheter infection a few days into the
study (before receiving any ghrelin) – he was therefore
withdrawn and excluded from analysis.
The primary study outcome was spontaneous energy
intake at protocol study meals on days 1 and 8 of the ghrelin
and saline administration periods. Energy intake at day 1
study meals (Figure 2a) was significantly higher after ghrelin
administration compared with saline (576±68 vs
484±65 kcal, Po0.001) with an average energy increase of
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Figure 1 | Study protocol. The flow of participants through the
study and numbers at each stage are shown.
Table 1 | Baseline characteristics of participants
Age
(years) Sex Disease Vintage Modality Kt/V BMI kg/m2 Alb g/l Chol mmol/l TIBC lmol/l SGA score Weight loss Ghrelin week
36 M Unknown 4 HD 1.83 21 39 3.2 44 6 N 1
40 M Unknown 14 HD 1.84 20 36 4.9 38 5 Y 1
65 M HT 4 HD 1.40 27 34 Statin 40 5 Y 1
22 M Lupus 7 HD 1.85 19 34 1.8 33 6 N 2
48 M Lupus 2 HD 1.47 27 30 5.5 40 6 N 2
71 M HT 3 PD 2.60 29 28 Statin 42 6 N 1
57 M Diabetes 9 HD 1.80 25 33 Statin 35 6 Y 1
63 F Alport’s 1 HD 1.48 33 34 Statin 22 6 N 2
63 M PKD 8 HD 1.52 21 29 Statin 34 5 Y 2
39 F HIV 1 PD 2.62 24 21 5.3 44 6 N 1
48 F FJHN 2 PD 2.73 22 32 Statin 42 6 N 2
41 M PKD 2 HD 1.70 24 39 Statin 46 5 Y 2
BMI, body mass index; Chol, cholesterol; FJHN, familial juvenile hyperuricemic nephropathy; HD, hemodialysis; HIV, human immunodeficiency virus; HT, hypertension; Kt/V,
dialysis dose (weekly for PD); PD, peritoneal dialysis; PKD, polycystic kidney disease; SGA, subjective global assessment; TIBC, total iron-binding capacity.
Criteria used to define malnutrition for each patient are shaded. Weight loss was defined as 45% over 6 months.
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Figure 2 | Energy intake with saline compared with ghrelin. (a)
Study meals at the start of saline and ghrelin weeks showing an
increase in energy intake after the first injection (individual values
and mean±s.e., Po0.001); (b) study meals at the end of saline
and ghrelin weeks showing persistence of the increase in energy
intake (Po0.001); and (c) food diaries during both weeks showing
a consistent effect throughout the diurnal period (mean±s.e.,
P¼ 0.040). *Po0.05; ***Po0.01.
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20.3% (90% confidence interval: 10.3–31.2%). At day 8 study
meals (Figure 2b), after a week of daily administration,
energy intake was similarly increased following ghrelin
administration compared with saline (621±74 vs
499±61 kcal, Po0.001) with an average energy increase of
24.6% (90% confidence interval: 12.6–37.9%).
To examine the effect on food intake throughout the
interdose interval, midway through each week participants
kept a 72 h food diary – these were subsequently analyzed in
blinded manner. Mean daily energy intake (Figure 2c) was
19.0% greater during the week of ghrelin administration
compared with the saline week (P¼ 0.040, 90% confidence
interval: 1.2–39.8%). There was no change in the proportion
of total calories derived from protein (17.4 vs 16.3% for the
saline and ghrelin weeks, respectively).
Following administration of ghrelin, plasma total ghrelin
levels increased 8-fold, from 1.8±0.3 at baseline to
14.6±1.4 nmol/l at 30 min, whereas acyl ghrelin levels
increased 80-fold, from 11.1±3.2 to 912±129 pmol/l.
Acyl ghrelin was rapidly cleared from the circulation, leaving
elevated levels of total ghrelin for the duration of the
monitoring period (Figure 3). Bioactivity of the peptide
preparation was confirmed by the measurement of plasma
growth hormone, which increased from 3.2±0.9 at baseline
to 56.3±10.9 mU/l at 30 min (Po0.001). There was no
reduction in growth hormone response to ghrelin at the end
of the week (58.4±18.6 vs 54.5±14.6 mU/l for days 1 and 8,
respectively) but despite this, there was no change in
circulating levels of insulin-like growth factor 1 (Table 2).
Baseline plasma leptin levels were high at 56.8±14.3 mg/l and
were unchanged by ghrelin administration.
Changes in energy intake are often compensated by
changes in activity-related energy expenditure to maintain
homeostasis. We therefore measured activity thermogenesis
(AT) using free-living heart and motion monitors attached to
the participants’ chest wall throughout each study week.
There was no significant difference between AT during the
ghrelin and saline weeks (425±76 vs 385±70 kcal/day,
P¼ 0.37). A representative portion of the data output from
one patient during ghrelin and saline administration is
shown in Figure 4.
Blood pressure was measured during days 1 and 8 study
meals: at both time points, there was a significant reduction
in systolic and diastolic blood pressure over 60 min after
ghrelin injection with average reductions of 10.4 mm Hg
systolic and 4.7 mm Hg diastolic (P¼ 0.032 and 0.018,
respectively). Participants also kept home blood pressure
records throughout the study weeks, which confirmed
differences between blood pressure 1 h after ghrelin or saline
administration (systolic 134.7±4.4 vs 140.2±4.8 mm Hg
and diastolic 78.2±2.4 vs 83.2±3.2 mm Hg), due to a
reduction in blood pressure from baseline in the ghrelin
group (P¼ 0.049 and 0.032 for systolic and diastolic,
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Figure 3 | Ghrelin plasma levels following injection. Following
subcutaneous administration of acyl ghrelin 12 mg/kg, there was a
prompt increase in total ghrelin levels and acyl ghrelin in
particular. The acyl ghrelin appeared to be more rapidly cleared
(mean±s.e.).
Table 2 | Cytokines and routine laboratory variables during the study
End-of-the-week level Change during the week
Saline Ghrelin Sig Saline Ghrelin Sig
IL-6 (pg/ml) 1.37±0.23 1.56±0.28 0.34 +0.01±0.15 +0.19±0.22 0.49
TNFa (pg/ml) 18.7±4.7 19.1±4.3 0.82 +0.3±1.3 +0.5±1.8 0.96
IGF-1 (nmol/l) 23.7±4.5 24.1±3.6 0.88 1.2±1.7 1.9±1.3 0.76
Hb (g per 100 ml) 12.64±0.39 12.54±0.41 0.68 +0.00±0.11 0.12±0.24 0.68
Lp (10e9/l) 1.7±0.2 2.0±0.3 0.20 +0.0±0.1 +0.2±0.2 0.26
Np (10e9/l) 4.1±0.5 4.5±0.6 0.07 0.1±0.3 +0.2±0.3 0.17
Alb (g/l) 37.5±1.8 37.8±2.2 0.62 +0.4±0.6 +0.0±0.4 0.60
Chol (mmol/l) 4.36±0.50 4.63±0.44 0.48 0.15±0.14 0.03±0.14 0.13
CRP (mg/l) 18.1±8.1 18.6±6.6 0.94 +6.8±7.9 +5.3±2.7 0.83
Ca (mmol/l) 2.29±0.04 2.33±0.04 0.36 0.04±0.02 +0.01±0.05 0.48
PO4 (mmol/l) 1.88±0.16 1.85±0.17 0.78 +0.05±0.05 0.24±0.21 0.42
ALP (IU/l) 119.0±21.5 115.1±21.1 0.15 +2.1±2.9 4.0±3.2 0.13
ALP, alkaline phosphatase; Alb, albumin; Chol, cholesterol; CRP, C reactive protein; Hb, hemoglobin; IGF-1, insulin-like growth factor 1; IL-6, interleukin 6; Lp, lymphocyte
count; Np, neutrophil count; TNFa, tumor necrosis factor-a.
The levels of routinely measured laboratory variables in participants during the study. Both the absolute level and the change during the week are given as mean±s.e.
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respectively). Blood pressure changes had resolved by 2 h
after injection (Figure 5).
Few adverse events were experienced during the study and
the majority were unaware of their treatment allocation. One
patient reported mild abdominal discomfort on two occa-
sions during the ghrelin week, but bowel frequency remained
the same in all patients. Two patients experienced a dose-
related syndrome, both reporting a strong feeling of hunger
within 5 min of their first ghrelin injection, associated with
lethargy and sleepiness – there was no change in blood
glucose, and no change in blood pressure in one patient, but
a 25 mm Hg drop in systolic pressure to 115/68 in the other.
These symptoms resolved during the first hour and were
subsequently managed with dose reductions – at 25% of the
original dose symptoms were absent, or minimal. Clearly, the
occurrence of these symptoms unblinded these participants.
There were no differences in fasting or postprandial
glucose between the study weeks, and no change in plasma
glucose or insulin levels during the 30 min interval
following ghrelin administration, before the study meal.
After the meal, glucose and insulin levels increased: mean
levels of both were slightly, but not significantly, higher
following ghrelin than following saline, perhaps reflecting the
difference in calorie intake (Figure 6). Circulating levels of the
proinflammatory cytokines interleukin-6 and tumor necrosis
factor-a were unchanged by a week of ghrelin administration
(Table 2). There were no significant changes in routinely
measured blood tests, including biochemical markers of
nutrition, such as albumin and cholesterol (Table 2). Body
weight was not measured as, over the timescale of this study, it
would reflect fluid status rather than nutritional state.
DISCUSSION
This study shows that subcutaneous ghrelin leads to an
immediate increase in energy intake of over 20% at the
following meal in malnourished dialysis patients – this occurs
without diurnal compensation so that energy intake over the
whole day is increased, and shows no sign of tolerance after
multiple injections.
The fact that the response to ghrelin was not diminished
after multiple daily injections is of crucial clinical importance
as nutritional improvement is clearly dependent on a
sustained effect. The usual response to over or under feeding
involves appetite compensation within a few days to restore
energy balance. Thus, many agents that have initially shown
promise for obesity or cachexia have been found to have a
relatively short-lived effect, with reduced responses occurring
within a few doses.25 Homeostatic adjustment of food intake
may account for the equivocal results from studies of
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long-term nutritional supplementation,26–28 as increases in
total energy intake are not likely to be sustained once
compensatory changes in appetite occur. This is most clearly
shown in a recent study of intradialytic parenteral nutri-
tion,29 in which initiation of supplements led to a
compensatory reduction in spontaneous food intake.
It is also important that the measured component of
thermogenesis (energy expenditure) was not increased, as
this suggests a positive change in energy balance. AT may be
most important in this regard as this component has been
shown to be regulated by nutritional state, and to account for
much of the the variability in individual responses to changes
in food intake.30 Moreover, it has become apparent that a
number of appetite regulators, such as the gastrointestinal
anorectic signal oxyntomodulin, are also involved in the
regulation of AT.31 The Actiheart is a reliable and validated
monitor, which calculates ‘free-living’ AT by continuous
accelerometry and measurement of pulse rate,32 and is
calibrated separately for each individual by a short exercise
test. It may be argued that the large part of AT consisting of
incidental or non-exercise AT, often termed ‘NEAT’ (which
includes energy expended in all activities beyond resting,
which are not considered as exercise), may not be adequately
reflected by pulse and motion monitoring; however, the
Actiheart has been found to compare well with indirect
calorimetry even during very light acivities, such as standing
or typing on a computer.33 We did not measure resting
thermogenesis in this study – this is usually a static
component in healthy individuals, and is thought to be
unchanged, or minimally lowered by ghrelin.34,35
Earlier studies have identified increased circulating ghrelin
concentrations in the presence of anorexia in patients with
chronic kidney disease, and consequently, a state of ghrelin
resistance has been suggested.36 In this context, it may seem
counter-intuitive to attempt administration of higher con-
centrations of ghrelin, but this study provides a rationale for
this approach. Ghrelin is secreted with an acyl side chain on
the third serine amino acid, which is essential for its
neuroendocrine action, and which is rapidly removed in
the plasma, forming desacyl ghrelin. The high levels of
ghrelin shown in chronic kidney disease have been postulated
to represent desacyl ghrelin.37 We found normal baseline
levels of acyl ghrelin, with a greatly reduced acyl to total
ghrelin ratio, confirming that the excess ghrelin in the plasma
of dialysis patients is predominantly in the desacyl form.
Administration of exogenous ghrelin disproportionately
elevates acyl ghrelin levels and increases acyl to total ghrelin
ratio. This may be especially important, as some studies
suggest a possible appetite inhibitory effect of desacyl
ghrelin.38 We did not find evidence of ghrelin resistance in
dialysis patients, consistent with our observation that ghrelin
administration at the same dose is of similar efficacy to that
reported in controls.21
Circulating ghrelin increases appetite largely by stimulat-
ing NPY and AgRP neurons in the hypothalamus and acts
through GHS receptors on vagal afferents.39,40 Ghrelin
therefore has a direct influence on appetite regulation, in
contrast to existing appetite stimulants which act indirectly
and are therefore associated with a range of unwanted effects.
There is no immediate change in appetite with megestrol
acetate, for example, but increases in energy intake of around
15% have been reported after some weeks,41 with weight
gains of around 3 kg over 3 months.42,43 However, a quarter
of patients are unresponsive,44,45 a range of steroid-like side
effects can occur, and most of the weight gained is fat rather
than lean tissue.46 Acting more directly, ghrelin appears
capable of increasing both lean and fat tissues, as shown in
rodent models of cancer47 and chronic kidney disease.48
However, several studies found only increases in adiposity,49
consistent with the direct adipogenic effects which have been
demonstrated,50 and enthusiasm should also be balanced by
the potential for other metabolic effects, including reduced
insulin sensitivity, either dependent or independent of
growth hormone release.51 In this study, glucose and insulin
levels appeared unaffected by ghrelin administration, and
insulin-like growth factor 1 levels remained similar despite
the large increase in growth hormone. However, reassurance
from this short-term study should be considered in the light
of the modest decrease in insulin sensitivity which was
reported in a longer duration study using an oral ghrelin
mimetic.52
Blood pressure was modestly reduced by ghrelin, in
agreement with a number of studies showing reduced blood
pressure, as much as by 9–12 mm Hg when given intrave-
nously.53,54 The precise mechanism of this effect is unclear,
but evidence suggests it is secondary to vasodilation, with no
change in pulse rate and an increase in peripheral
perfusion,55 and cardiac output.53 Unlike the hypotensive
effect of growth hormone through insulin-like growth
factor 1, it appears to be independent of nitric oxide.55 It
has been suggested that this action may be therapeutically
useful in patients with heart failure, and preliminary studies
in human subjects support this possibility,56 but its
importance in dialysis patients requires further clarification.
Ghrelin is also thought to possess anti-inflammatory
activity: in vitro experiments have clearly shown that ghrelin
suppresses the release of inflammatory cytokines by stimu-
lated monocytes and lymphocytes,57,58 and in vivo studies
have confirmed this effect in a number of rodent models of
inflammation, including chemically induced colitis, pancrea-
titis, or arthritis.59–62 Although levels of circulating inflam-
matory cytokines were elevated as anticipated in our study
participants, we did not observe any changes as a result of
ghrelin administration. However, these simple measurements
would have little power to detect changes in dynamic
immune responses and should not be taken as evidence
against a physiologically relevant effect.
This is the first demonstration of persistent changes in
energy balance in response to ghrelin administration in
malnourished dialysis patients. This strategy therefore has the
potential to reverse the complication of chronic dialysis most
closely associated with poor outcome, and these data are also
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of relevance to other chronic illnesses in which mortality is
strongly linked to malnutrition, such as heart failure63,64 and
emphysema.65 This study was small, however, and its
duration was not sufficient to demonstrate significant
changes in nutritional status such as increased body weight.
Crucially, it remains unknown whether correction of the
negative energy balance in malnourished dialysis patients will
lead to improvements in clinical outcome. Just as dissociation
of total energy balance from altered protein metabolism has
been shown in uremic models,66 so detrimental metabolic
changes associated with malnutrition may persist despite
correction of negative energy balance. Until now however,
without a reliable mechanism for achieving a sustained
improvement in energy balance, this hypothesis has been
difficult to test. Longer-term studies involving ghrelin or
ghrelin agonists are needed to address this important issue,
and would be facilitated by the availability of an oral agent –
the recent publication of promising appetite results with a
small molecule analog is therefore of great interest.67
The degree of appetite increase, which is similar to the
20–31% range seen in healthy volunteers68,69 and patients
with metastatic cancer,70 is also important, as even relatively
small changes in appetite can have a dramatic effect on body
weight when sustained over time. The excess energy intake
required to increase body weight by 1 kg in healthy
individuals is in the order of 10,000 kcal,71 which, even
accounting for the low intake of the patients in this study
(1783±133 kcal per day), represents a 20% increase in energy
intake over a month. One might therefore expect measurable
changes in weight and other parameters over relatively short
periods, such as 2 or 3 months. The high response rate, with
all patients increasing their meal energy intake except one at
each meal (a different patient at the start and end of the
week) is also important in this regard.
In conclusion, we have demonstrated a sustained
improvement in energy balance in malnourished dialysis
patients using the orexigenic hormone ghrelin. This novel
approach, which directly targets appetite regulation, could
have an important role in the future management and
prevention of malnutrition in dialysis patients.
MATERIALS AND METHODS
This study was designed to test the nutritional and cardiovascular
effects of 1 week of ghrelin administration. It therefore compared
ghrelin with saline in a crossover design, each being subcutaneously
administered once daily for 8 days, in random order, with allocation
concealed from participants and investigators. It was conducted in
accordance with the ethical principles of the declaration of Helsinki,
and formally approved by the local NHS Research Ethics Committee
(05/Q0401/132). All participants gave their informed consent before
taking part, and the trial was internationally registered before
recruitment began (ISRCTN43319045).
Chemically synthesized human acyl-ghrelin was purchased
(Bachem, St Helens, UK), dissolved in water, and freeze-dried in
individual dose aliquots (0.925 mg per vial). The batch was then
subjected to a series of quality control assays, including amino-acid
content by mass spectrometry (Alta Bioscience, Edgebaston,
Birmingham, UK), endotoxin analysis by the limulus amoebocyte
lysate assay (Cape Cod, Liverpool, UK) and microbiological culture.
Toxicity was further tested by intraperitoneal injection of a 20-fold
dose into mice, with subsequent killing and histological examination
of internal organs. Placebo vials were prepared by freeze-drying
100 ml 0.9% saline, which gives a similar appearance to the peptide
vials. All vials were then coded by a member of the department not
involved in the study, so that ghrelin and saline treatment weeks
occurred in random order with concealed allocation.
In a large renal center with several satellite dialysis facilities,
eligible patients were identified from hospital records and invited to
participate while attending for dialysis or by telephone. Patients
were considered eligible if aged between 18 and 75 years, clinically
well, and at least two of the following markers of malnutrition were
present: unintentional weight loss of 45% over the past 6 months;
serum albumin o35 g/l; untreated cholesterol o4.5 mmol/l; body
mass indexo20 kg/m2; subjective global assessment scoreo6; total
iron-binding capacity o45%.
Recruited patients first entered a screening period, during which
they were taught and practiced subcutaneous self-injection and food
diary recording, and attended the facility for a study meal.
Participants proceeded into the study if confident with self-
injection. They then received their coded vials and underwent both
intervention periods (ghrelin and saline) separated by a washout
interval of at least 1 week. During each week, participants
reconstituted and administered one injection each day, using a
volume calculated to give a ghrelin dose of 12 mg/kg, given 1 h before
a meal, avoiding periods immediately before hemodialysis. Each
‘week’ ran from days 1–8, so that the intervention and study meal on
the first and last day were carried out during the same dialysis phase.
All hemodialysis participants were on thrice weekly schedules,
receiving at least 4 h per session. Therapeutic parameters, such as
dry weight, were kept constant throughout the study, with study
meals carried out on non-dialysis days. Peritoneal dialysis schedules
were also kept constant: study meals were carried out with a dwell
volume of 2 l, 3 h after the last exchange, which was 1.36% glucose in
two participants and icodextrin in the other.
Energy intake was measured by study meals and food diaries. On
the first and last days of each week, participants attended the study
facility after a 12 h fast, to have their injection, followed after 30 min
by a study meal. The meal type had been selected and tested during
the screening period, so that each participant gave their meal a
medium palatability score, and used the same meal type throughout
the study. Meals were of uniform calorie density so that energy
intake could be reliably calculated from weight consumed, and were
always served well in excess of expected intake, with water ad
libitum. During the week, participants administered their injections
at home, keeping a food intake diary for 3 consecutive days. Food
diaries were analyzed with Dietplan 5 (Forrest Hill Software Ltd,
Sussex, UK) before unmasking the randomization.
Blood pressure was measured over the first hour, at the study
facility on the first and last day, and also recorded by participants at
home during the week at various times after injection.
Energy expenditure was measured using Actiheart pulse and
motion monitors (Cambridge Neurotechnology, Papworth, UK;
Figure 4), which were worn on the chest wall throughout each
intervention period. The relationship between heart rate and
workload was established for individual participants using a short
exercise test – this correlation was then used to calibrate each
monitor. Activity-related energy expenditure was calculated using
branched-modelled equations giving a variable weighting to the
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parameters of pulse rate and movement according to the ambient
heart rate.72
Plasma total ghrelin was measured using an established in-house
radioimmune assay, and acyl ghrelin by sandwich enzyme-linked
immunosorbent assay (Sceti Co., Tokyo, Japan). Plasma leptin was
measured by radioimmune assay (Linco, St Charles, MO, USA). The
cytokines interleukin-6 and tumor necrosis factor-a were chosen, as
these are known to induce anorexia, and were measured by
sandwich enzyme-linked immunosorbent assay (R&D Systems,
Abingdon, UK).
Paired sample t-tests were used to compare energy intakes
measured at study meals and average daily intake estimated by food
diaries. Blood pressures recorded at multiple time points over the
first hour on study days were analyzed by analysis of variance. Daily
home blood pressure readings were averaged within patients to
preserve independence, with the baseline and 1 h time points
compared by paired sample t-test. Data are represented as
mean±s.e.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
DRA was supported by a translational medicine fellowship from
the Hammersmith Hospitals Trustees Research Committee. This
research was funded by programme grants from the MRC (G7811974)
and Wellcome Trust (072643/Z/03/Z) and by an EU FP6 Integrated
Project Grant (LSHM-CT-2003-503041). We are also grateful for
support from the NIHR Biomedical Research Centre funding scheme
and an IMB Capacity Building Award. We are grateful to Professor G
Stamp for reviewing murine histology, as well as to Sara Alsaraf,
Qihua Liu, Tara Watson, Claire Edwards, Kate Reed, and Margaret
Nevin for their assistance. Part of this work was the subject of an
oral presentation at the American Society of Nephrology Renal
Week 2007.
REFERENCES
1. Garg AX, Blake PG, Clark WF et al. Association between renal insufficiency
and malnutrition in older adults: results from the III NHANES. Kidney Int
2001; 60: 1867–1874.
2. Kopple JD, Greene T, Chumlea WC et al. Relationship between nutritional
status and the glomerular filtration rate: results from the MDRD study.
Kidney Int 2000; 57: 1688–1703.
3. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis
patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62:
2238–2245.
4. Port FK, Ashby VB, Dhingra RK et al. Dialysis dose and body mass index
are strongly associated with survival in hemodialysis patients. J Am Soc
Nephrol 2002; 13: 1061–1066.
5. Marcen R, Teruel JL, de la Cal MA et al. The impact of malnutrition in
morbidity and mortality in stable haemodialysis patients. Spanish
Cooperative Study of Nutrition in Hemodialysis. Nephrol Dial Transplant
1997; 12: 2324–2331.
6. Acchiardo SR, Moore LW, Latour PA. Malnutrition as the main factor in
morbidity and mortality of hemodialysis patients. Kidney Int Suppl 1983;
16: S199–S203.
7. Fleischmann E, Teal N, Dudley J et al. Influence of excess weight on
mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999;
55: 1560–1567.
8. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of
cardiovascular risk factors in maintenance dialysis patients. Kidney Int
2003; 63: 793–808.
9. Avram MM, Sreedhara R, Fein P et al. Survival on hemodialysis and
peritoneal dialysis over 12 years with emphasis on nutritional parameters.
Am J Kidney Dis 2001; 37: S77–S80.
10. Mittman N, Avram MM, Oo KK et al. Serum prealbumin predicts survival in
hemodialysis and peritoneal dialysis: 10 years of prospective observation.
Am J Kidney Dis 2001; 38: 1358–1364.
11. Iseki K, Yamazato M, Tozawa M et al. Hypocholesterolemia is a significant
predictor of death in a cohort of chronic hemodialysis patients. Kidney Int
2002; 61: 1887–1893.
12. Kamimura MA, Draibe SA, Avesani CM et al. Resting energy expenditure
and its determinants in hemodialysis patients. Eur J Clin Nutr 2007; 61:
362–367.
13. Kalantar-Zadeh K, Block G, McAllister CJ et al. Appetite and inflammation,
nutrition, anemia, and clinical outcome in hemodialysis patients. Am J
Clin Nutr 2004; 80: 299–307.
14. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin
signaling in uremia-associated cachexia. J Clin Invest 2005; 115:
1659–1665.
15. Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and
increases food intake in humans. J Clin Endocrinol Metab 2001;
86: 5992.
16. Cummings DE, Purnell JQ, Frayo RS et al. A preprandial rise in plasma
ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;
50: 1714–1719.
17. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-
induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:
1623–1630.
18. le Roux CW, Patterson M, Vincent RP et al. Postprandial plasma ghrelin is
suppressed proportional to meal calorie content in normal-weight but
not obese subjects. J Clin Endocrinol Metab 2005; 90: 1068–1071.
19. Ashby D, Choi P, Bloom S. Gut hormones and the treatment of disease
cachexia. Proc Nutr Soc 2008; 67: 1–7.
20. Wren AM, Small CJ, Ward HL et al. The novel hypothalamic peptide
ghrelin stimulates food intake and growth hormone secretion.
Endocrinology 2000; 141: 4325–4328.
21. Druce MR, Neary NM, Small CJ et al. Subcutaneous administration of
ghrelin stimulates energy intake in healthy lean human volunteers. Int J
Obes (Lond) 2005.
22. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents.
Nature 2000; 407: 908–913.
23. Wren AM, Small CJ, Abbott CR et al. Ghrelin causes hyperphagia and
obesity in rats. Diabetes 2001; 50: 2540–2547.
24. Wynne K, Giannitsopoulou K, Small CJ et al. Subcutaneous ghrelin
enhances acute food intake in malnourished patients who receive
maintenance peritoneal dialysis: a randomized, placebo-controlled trial.
J Am Soc Nephrol 2005; 16: 2111–2118.
25. Sartorio A, Conti A, Ferrero S et al. GH responsiveness to repeated GHRH
or hexarelin administration in normal adults. J Endocrinol Invest 1995; 18:
718–722.
26. Caglar K, Fedje L, Dimmitt R et al. Therapeutic effects of oral nutritional
supplementation during hemodialysis. Kidney Int 2002; 62: 1054–1059.
27. Kloppenburg WD, Stegeman CA, Hovinga TK et al. Effect of prescribing a
high protein diet and increasing the dose of dialysis on nutrition in stable
chronic haemodialysis patients: a randomized, controlled trial. Nephrol
Dial Transplant 2004; 19: 1212–1223.
28. Dombros NV. Chronic intraperitoneal administration of amino acids does
not improve the nutritional status of malnourished continuous
ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13(Suppl 2):
S487–S490.
29. Cano NJ, Fouque D, Roth H et al. Intradialytic parenteral nutrition does
not improve survival in malnourished hemodialysis patients: a 2-year
multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18:
2583–2591.
30. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity
thermogenesis in resistance to fat gain in humans. Science 1999; 283:
212–214.
31. Wynne K, Park AJ, Small CJ et al. Oxyntomodulin increases energy
expenditure in addition to decreasing energy intake in overweight and
obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30:
1729–1736.
32. Brage S, Brage N, Franks PW et al. Reliability and validity of the combined
heart rate and movement sensor Actiheart. Eur J Clin Nutr 2005; 59:
561–570.
33. Crouter SE, Churilla JR, Bassett Jr DR. Accuracy of the Actiheart for the
assessment of energy expenditure in adults. Eur J Clin Nutr 2008; 62:
704–711.
34. Asakawa A, Inui A, Kaga T et al. Ghrelin is an appetite-stimulatory signal
from stomach with structural resemblance to motilin. Gastroenterology
2001; 120: 337–345.
35. St-Pierre DH, Karelis AD, Cianflone K et al. Relationship between ghrelin
and energy expenditure in healthy young women. J Clin Endocrinol Metab
2004; 89: 5993–5997.
Kidney International (2009) 76, 199–206 205
DR Ashby et al.: Ghrelin in malnourished dialysis patients o r i g i n a l a r t i c l e
36. Chang CC, Hung CH, Yen CS et al. The relationship of plasma ghrelin level
to energy regulation, feeding and left ventricular function in non-diabetic
haemodialysis patients. Nephrol Dial Transplant 2005; 20: 2172–2177.
37. Yoshimoto A, Mori K, Sugawara A et al. Plasma ghrelin and desacyl
ghrelin concentrations in renal failure. J Am Soc Nephrol 2002; 13:
2748–2752.
38. Asakawa A, Inui A, Fujimiya M et al. Stomach regulates energy balance via
acylated ghrelin and desacyl ghrelin. Gut 2005; 54: 18–24.
39. Kamegai J, Tamura H, Shimizu T et al. Chronic central infusion of ghrelin
increases hypothalamic neuropeptide Y and Agouti-related protein
mRNA levels and body weight in rats. Diabetes 2001; 50: 2438–2443.
40. Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central
regulation of feeding. Nature 2001; 409: 194–198.
41. Von Roenn JH, Murphy RL, Weber KM et al. Megestrol acetate for
treatment of cachexia associated with human immunodeficiency virus
(HIV) infection. Ann Intern Med 1988; 109: 840–841.
42. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone
decanoate and dietary counselling for HIV associated weight loss. Int J
Androl 2001; 24: 232–240.
43. Vadell C, Segui MA, Gimenez-Arnau JM et al. Anticachectic efficacy of
megestrol acetate at different doses and versus placebo in patients with
neoplastic cachexia. Am J Clin Oncol 1998; 21: 347–351.
44. Jatoi A, Rowland K, Loprinzi CL et al. An eicosapentaenoic acid
supplement versus megestrol acetate versus both for patients with
cancer-associated wasting: a North Central Cancer Treatment Group and
National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;
22: 2469–2476.
45. Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol
acetate versus combination therapy for cancer-associated anorexia: a
North Central Cancer Treatment Group study. J Clin Oncol 2002; 20:
567–573.
46. Oster MH, Enders SR, Samuels SJ et al. Megestrol acetate in patients with
AIDS and cachexia. Ann Intern Med 1994; 121: 400–408.
47. Deboer MD, Zhu XX, Levasseur P et al. Ghrelin treatment causes increased
food intake and retention of lean body mass in a rat model of cancer
cachexia. Endocrinology 2007; 148: 3004–3012.
48. Deboer MD, Zhu X, Levasseur PR et al. Ghrelin treatment of chronic
kidney disease: improvements in lean body mass and cytokine profile.
Endocrinology 2008; 149: 827–835.
49. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents.
Nature 2000; 407: 908–913.
50. Theander-Carrillo C, Wiedmer P, Cettour-Rose P et al. Ghrelin action in the
brain controls adipocyte metabolism. J Clin Invest 2006; 116: 1983–1993.
51. Vestergaard ET, Gormsen LC, Jessen N et al. Ghrelin infusion in humans
induces acute insulin resistance and lipolysis independent of GH-
signaling. Diabetes 2008; 57: 3205–3210.
52. Nass R, Pezzoli SS, Oliveri MC et al. Effects of an oral ghrelin mimetic on
body composition and clinical outcomes in healthy older adults: a
randomized trial. Ann Intern Med 2008; 149: 601–611.
53. Nagaya N, Miyatake K, Uematsu M et al. Hemodynamic, renal, and
hormonal effects of ghrelin infusion in patients with chronic heart failure.
J Clin Endocrinol Metab 2001; 86: 5854–5859.
54. Nagaya N, Kojima M, Uematsu M et al. Hemodynamic and hormonal
effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr
Comp Physiol 2001; 280: R1483–R1487.
55. Okumura H, Nagaya N, Enomoto M et al. Vasodilatory effect of ghrelin, an
endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002; 39:
779–783.
56. Nagaya N, Moriya J, Yasumura Y et al. Effects of ghrelin administration on
left ventricular function, exercise capacity, and muscle wasting in patients
with chronic heart failure. Circulation 2004; 110: 3674–3679.
57. Dixit VD, Schaffer EM, Pyle RS et al. Ghrelin inhibits leptin- and activation-
induced proinflammatory cytokine expression by human monocytes and
T cells. J Clin Invest 2004; 114: 57–66.
58. Li WG, Gavrila D, Liu X et al. Ghrelin inhibits proinflammatory responses
and nuclear factor-kappaB activation in human endothelial cells.
Circulation 2004; 109: 2221–2226.
59. Dembinski A, Warzecha Z, Ceranowicz P et al. Ghrelin attenuates the
development of acute pancreatitis in rat. J Physiol Pharmacol 2003; 54:
561–573.
60. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a
mouse model of colitis. Gastroenterology 2006; 130: 1707–1720.
61. Granado M, Priego T, Martin AI et al. Anti-inflammatory effect of the
ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic
rats. Am J Physiol Endocrinol Metab 2005; 288: E486–E492.
62. Kasimay O, Iseri SO, Barlas A et al. Ghrelin ameliorates pancreaticobiliary
inflammation and associated remote organ injury in rats. Hepatol Res
2006; 36: 11–19.
63. Akashi YJ, Springer J, Anker SD. Cachexia in chronic heart failure:
prognostic implications and novel therapeutic approaches. Curr Heart Fail
Rep 2005; 2: 198–203.
64. Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia.
Nutr Rev 1994; 52: 340–347.
65. Landbo C, Prescott E, Lange P et al. Prognostic value of nutritional status
in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;
160: 1856–1861.
66. Cheung WW, Rosengren S, Boyle DL et al. Modulation of melanocortin
signaling ameliorates uremic cachexia. Kidney Int 2008; 74: 180–186.
67. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a
novel, orally available ghrelin mimetic and growth hormone
secretagogue: results of a phase I, randomized, placebo-controlled,
multiple-dose study in healthy volunteers. Oncologist 2007; 12: 594–600.
68. Druce MR, Wren AM, Park AJ et al. Ghrelin increases food intake in obese
as well as lean subjects. Int J Obes Relat Metab Disord 2005; 29:
1130–1136.
69. Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and
increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
70. Neary NM, Small CJ, Wren AM et al. Ghrelin increases energy intake in
cancer patients with impaired appetite: acute, randomized, placebo-
controlled trial. J Clin Endocrinol Metab 2004; 89: 2832–2836.
71. Diaz EO, Prentice AM, Goldberg GR et al. Metabolic response to
experimental overfeeding in lean and overweight healthy volunteers. Am
J Clin Nutr 1992; 56: 641–655.
72. Brage S, Brage N, Franks PW et al. Branched equation modeling of
simultaneous accelerometry and heart rate monitoring improves
estimate of directly measured physical activity energy expenditure. J Appl
Physiol 2004; 96: 343–351.
206 Kidney International (2009) 76, 199–206
o r i g i n a l a r t i c l e DR Ashby et al.: Ghrelin in malnourished dialysis patients
